Skip to main content
NACFC 2025 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Session includes an in person invitee/speaker with CF
Session includes an in person invitee/speaker with CF
Livestreamed Session
Livestreamed Session
Recorded Session
Recorded Session
Session is Ticketed (Must Register for Session through Registration)
Session is Ticketed (Must Register for Session through Registration)
Food Available for Session Attendees
Food Available for Session Attendees

Daniel P. Cook, MD, PhD

University of Iowa

Daniel Cook, MD, PhD is a physician-scientist and Assistant Professor in the Division of Pulmonary, Critical Care, and Occupational Medicine at the University of Iowa where he directs a research program focused on epithelial, innate, and adaptive immune interactions in allergy.

Dr. Cook received his MD and PhD degrees at the University of Iowa. Following doctoral training, Dr. Cook joined the Tinsley Harrison Society at Vanderbilt University Medical Center (VUMC) where he received internal medicine training. He then completed a Pulmonary and Critical Care Medicine fellowship at VUMC. Dr. Cook later joined the clinical faculty at VUMC where he began a research program focused on identifying and understanding the mechanisms of increased allergy in cystic fibrosis (CF). His work has been supported by numerous grants including a NIAID K08, a LeRoy Matthews Physician Scientist Development Award, a Parker B. Francis Fellowship, a NIDDK P30, and a CF Foundation Faculty Development Award.

In 2024, Dr. Cook joined the faculty at the University of Iowa. Dr. Cook cares for adult patients with respiratory disorders in the Medical ICU and wards, an experience which fuels and innovates his laboratory research program. His team discovered increased mortality in persons with co-morbid allergic disease and CF compared to those individuals with CF lacking allergic inflammation (Cook, et al. Allergy). They then dissected the molecular consequences of loss of the cystic fibrosis transmembrane conductance regulator (CFTR), uncovering epithelial alarmin dysfunction (Cook, et al. AJRCCM) and adaptive immunity defects (Rusznak...Cook, JCI Insight). Dr. Cook is now pursing an innovative therapeutic strategy: using targeted biologic therapy in CF and CFTR modulation in allergic inflammation. By interfacing computational analysis of electronic health record data, precision-engineered mouse models, and cellular multi-omics, his lab is experimentally validating CFTR modulation as a promising target for patients suffering from allergic disease.

Presentation(s):